Volociximab

Volociximab is a monoclonal antibody for the treatment of cancer. It was developed by PDL BioPharma and is currently being developed by Biogen Idec and Facet Biotech.

Mechanism of action

Volociximab works by targeting alpha5beta1, an integrin that is present in high amounts on the surface of certain types of cancer cells. By binding to this integrin, volociximab can inhibit the growth of the cancer cells.

Clinical trials

Volociximab has been tested in Phase I and Phase II for the treatment of various types of cancer, including pancreatic cancer, melanoma, and lung cancer. The results of these trials have been promising, with some patients showing a significant reduction in tumor size.

Side effects

Like all drugs, volociximab can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and vomiting. Less common side effects include anemia, neutropenia, and thrombocytopenia.

Future development

The future development of volociximab will depend on the results of ongoing clinical trials. If these trials continue to show that the drug is safe and effective, it may be approved for use in the treatment of certain types of cancer.

See also

• Monoclonal antibodies
• Cancer treatment
• Clinical trials

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia